Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
- David M. O'Malley
- , Debra L. Richardson
- , Patrick S. Rheaume
- , Ritu Salani
- , Eric L. Eisenhauer
- , Georgia A. McCann
- , Jeffrey M. Fowler
- , Larry J. Copeland
- , David E. Cohn
- , Floor J. Backes
Research output: Contribution to journal › Article › peer-review
47
Link opens in a new tab
Scopus
citations